Telephone: (972)-2-6521557.
Cellular: (972)-50-7874799
Fax : (972)-2-6528242
E-Mail: hubert@012.net
General
Nationality: Israeli
Marital Status : Married + 2
Education
1983-1984 - Psychology, Hebrew University
1984-1990 - M.D. Hadassah University Hospital, Jerusalem, Israel
1995 - Board Exam, Oncology Part I
1997 - USMLE Qualification Parts I & II
1997 - Board Exam., Oncology & Radiotherapy Part II
Courses
9/96 - "Medical Oncology". ESO, Milan, Italy. (5 Days)
10/1997 - "Medical Oncology & Radiotherapy". UCSF & Stanford U., USA. (1 Month)
Professional Experience
Since April 2009: Head of Gastrointestinal Cancer Center
1998-Today: Senior Physician, Oncology Dept., Hadassah University Hospital.
1992-1997: Resident, Oncology Dept., Hadassah University Hospital.
1990-1991: Intern, Hadassah University Hospital.
Academic Experience
2004: Instructor, Doctoral Thesis "Multi Markers RT-PCR Assay for the Detection of minimal residual disease in Pleural Effusion of Breast Cancer Patients".
2004: Instructor, Doctoral Thesis: "Evaluating the activity of dexrazoxane, a cardio-protector in doxorubicin treated breast-cancer patients, by measuring serum troponin levels"
2001: Lecturer, Hebrew University, Jerusalem.
2000: Instructor, Research Thesis "The Prevalence of the Mutation BRCA2 8765 DEL AG in Yemenite Jews."
1999: Instructor, Doctoral Thesis "The influence of the I1307K mutation in the APC gene on the clinical presentation of breast and ovarian cancer in carriers of BRCA mutations.
1999: Member, Committee for Academic Examination in Medicine Medical School.
1997: Instructor, Medical Oncology/Radiation Oncology, Hebrew University, Jerusalem.
Membership in Professional Associations & Committees
§ Member of the Israel Society of Clinical Oncology
§ Member of the Israel Medical Society
§ Member, Israel Cancer Association; Committee for Gastrointestinal Cancer
§ Member, Israel Cancer Association; Committee for Medical and Social Services
Awards
Outstanding Lecturer in the School of Medicine, 2004.
The Landau Family Prize for Oncology Research, 1995.
Research Activities
Visiting GI Oncology Program. MD Anderson, Texas Medical Center, Houston, Texas. July 2003.
Book Chapters
Hubert A. “The therapeutic approach in treating gastric, esophageal and pancreatic cancer” in Innovations and updates in Gastric cancer. Figer A. (Ed.) P11-13, Aurora Group Press. 2001 (Hebrew)
Hubert A. "Treatment of antibodies in Gastrointestinal Cancer" BAMA, Isr.Canc.Soc. March 2005, 15:11-14.
Articles
Nissan A, Spira R, Hamburger T, Badriyyah M, Prus D, Cohen T, Hubert A. “Clinical profile of breats cancer in Arab and jewish women in the Jerusalem area.” Am.J.Surgery 2004, 188:62-67
Kaduri L, Kote-Jarai Z, Easton D, Hubert A. et al. “Polyglutamine repeat length in the AIBI gene modifies breast cancer susceptibility in BRCA1 carriers” Int J Cancer. 2004 Jan 20;108(3):399-403
Nisman B, Barak V, Hubert A, Kaduri L, Lyass O, Baras M, Peretz T. “Prognostic factors for survival in metastatic breast cancer during first-line paclitaxel chemotherapy”. Anticancer Res. 2003 Mar-Apr;23(2C):1939-42
Barak V, Nisman B, Hubert A, Lyass O, Peretz T. “Cytokeratins-Clinical Utility in Breast Cancer” J.Clin.Lig.Assay. Spring 2002, 25(1).
Rennert H, Bercovich D, Hubert A, Abeliovich D, Rozovsky U, Bar-Shira A, Soloviov S, Schreiber L, Matzkin H, Rennert G, Kadouri L, Peretz T, Yaron Y, Orr-Urtreger A. ”A Novel Founder Mutation in the RNASEL Gene, 471delAAAG, Is Associated with Prostate Cancer in Ashkenazi Jews.” Am. J Hum Genet. 2002 Jul 23; 71(4)
Shibolet O, Ilan Y, Hubert A, Shouval D, Safadi R. “Lamivudine therapy for prevention of immunosuppressive-induced hepatitis B virus reactivation in hepatitis B surface antigen carriers.” Blood. 2002 Jul 15; 100(2): 391-6
Lyass O, Hubert A, Gabizon A. “Phase I study of Doxil-Cisplatin chemotherapy in patients with advanced amlignancies.” Clin Cancer Res. 2001 Oct;7(10):3040-6.
Kadouri L, Kote-Jarai Z, Easton D.F, Durocher F, Hubert A, Hamoudi R, Abeliovich D, Glaser B, Peretz T, Eeles R.A. “CAG and GGC repeat polymorphisms in the androgen receptor gene and breast cancer susceptibility in BRCA1/2 carriers and non-carriers. Br J Cancer. 2001 Jul 6;85(1):36-40
Barak V, Nisman B, Hubert A, Lyass O, Kaduri L, Peretz T. "Prognostic efficiacy of TPS in breast cancer." J. of Tumor Marker Oncology. (In Press, 2000).
Lotem M, Hubert A, Lyass O, Goldhersch MA, Ingber A, Peretz T, Gabizon A. “Skin toxic effects of polyethylene glycol-coated liposomal Doxorubicin”. Arch Dermatol. 2000 Dec;136(12):1475-80
Hubert A, Lyass O, Podeh D, Gabizon A. "Doxil (Caelyx): an exploratory study with pharmokinetics in patients with hormone-refractory prostate cancer." Anti Cancer Drugs 2000, 11,123-127
Hubert A, Peretz T, Manor O, Kaduri L, Wienberg N, Lerer I, Sagi M, Abeliovich D. “The Jewish Ashkenazi founder mutations in the BRCA1/BRCA2 genes are not found at an increased frequency in prostate cancer Ashkenazi patients.” Am. J. Human Genetics.1999 Sep;65(3):921-924. (Letter)
Kaduri L, Gibs M, Hubert A, Sagi M, Heching N, Lerer I, Uziely B, Weinberg N, Abeliovich D, Peretz T. “Genetic testing of breast and ovarian cancer patients : Clinical characteristics and hormonal risk modifiers.” European J. Obstet.& Gyn. & Rep. Bio. N.85, P75-80. Jul. 99.
Lyass O, Gips M, Hubert A. “Small bowel metastases from lung cancer.” Harefua. V135: N10, Nov.15, 1998. (in Hebrew)
Wang T, Lerer I, Peretz Z, Sagi M, Kaduri L, Hubert A, Abeliovich D. “A BRCA2 Mutation 8558delA in an Ashkenazi breast cancer patient.” Human Mutation; Mutation and Polymorphism Report #22, 1998.
Barak V, Nisman B, Roisman I, Hubert A, Farbstein H, Baider L, Kaplan A, Halperin T, Stephanos S, Peretz T. “TPS in assessing response to therapy and prognosis of breast cancer patients treated with interferons” J. of Tumor Marker Oncology. Vol.12, No.4, Winter 1997.
Lyass O, Lossos A, Hubert A, Gips M, Peretz T. “Cisplatin - induced nonconvulsive encephalopathy.” Anti-Cancer Drugs, Vol.9. 1998.
Oren R. Zajicek G, Maaravi Y, Kenet G, Karmely F, Hubert A, Raanani P, Arber N. “Methimazole slows hepatocyte streaming in rats.” Dig.Dis.Sci. Jul;42(7):1433-7, 1997.
Peretz T, Kaplan Denour A, Baider L, Hubert A, Stephanos S, Barak V. "The combination of Interferon and Tamoxifen for patients with advanced breast cancer and negative estrogen receptors." The Breast. 6(4):190-193, 1997.
Oren R. Maaravi Y. Karmeli F. Kenet G. Zeidel L. Hubert A. Eliakim R. “Anti-thyroid drugs decrease mucosal damage in a rat model of experimental colitis.” Aliment Pharmacol. Ther. 11(2):341-5; Apr.1997.
Leker R. Peretz T. Hubert A. Lossos A. “Vincristine - induced paralytic illeus in Parkinson’s disease.” Parkinsonism & Related Disorders. Vol.3, No.2; 1997: 109-110.
Oren R, Zajicek G, Maaravi Y, Kenet G, Karmely F, Hubert A, Raanani P, Arber N. “Methimazole slows hepatocyte streaming in rats.” Dig Dis Sci. 1997 Jul;42(7):1433-7.
Oren R, Maaravi Y, Karmeli F, Kenet G, Zeidel L, Hubert A, Eliakim R. “Anti-thyroid drugs decrease mucosal damage in a rat model of experimental colitis.” Aliment Pharmacol. Ther. 1997 Apr;11(2):341-5.
Oren R. Beeri M. Hubert A. Kramer M. Matzner Y. “Effect of Theophylline on Erythocytosis in Chronic Obstructive Pulmonary Disease. Archives of Int. Med. 157(13): 1474-8;Jul.1997.
Hubert P. Livnat A. Hubert A. Sheffer N. “Arthroscopes”, Harefua, Feb. 1997. (In Hebrew)
Barak V. Nisman B. Roisman I. Hubert A. Burde B. Peretz T. “TPS in evaluation of response to Taxol in Interferon therapy in breast cancer patients.” J. Tumor Marker Oncology. 9(2):89, 1994.
Abstracts
Targeted Therapies in Metastatic Colorectal Cancer (MCRC): The Hadassah Experience
Hubert A. Kadouri L. Uzieli B. Gipps M. Peretz T. ISCORT 2005.
The risk of cancers other than Breast and Ovarian cancer amongst carriers of the BRCA 1/2 Ashkenazi founder mutations. Kaduri L, Hamburger T, Baras M, Hubert A, Abeliovich D, Peretz T. ESMU 2004.
Irinotecan (CPT11) combined with UFT as first line treatment of advanced colorectal carcinoma-A phase II study. Cohen Y. Shulman K. Idelevich E. Ben-Shachar M, Honnigman J, Haiat H, Zidan J. Hubert A. Kuten A, Beny A. J. Clin. Onc. ASCO 2004.
Weekly Paclitaxel in women with metastatic breast cancer.” Hubert A, Beer L, Gips M, Uzieli B, Peretz T. P-226. ISCORT-2, Eilat, Israel January 2003.
“The penetrance of BRCA1/BRCA2 mutations: comparison of the carrier rates in young and old age Ashkenazi indiviuals.” Hubert A, Abeliovich D, Shamshins L, Manor O, Sagi M, Kaduri L, Lerer I, Peretz T. P-220. ISCORT-2, Eilat, Israel January 2003.
“Prognosis and response to Herceptin by tumor markers in breast cancer.” Barak V, Nisman A, Hubert A, Lyass O, Peretz T. 19th Intl’ Conf. Human Tumor Markers, Denmark, August 2002.
“Final Results of a prospective randomized trial comparing 5-flourouracil with levamisole to 5-flourourasil with leucovorin as adjuvant therapy of colorectal cancer-the Israel cooperative oncology group (ICOG) study.” Peretz TH, Nissan A, Shain R, Borovick M, Steiner M, Baras M, Bar Chana M, Hubert A, Freund HR, Sulkes A, Figer A. ASCO, May 2002
“The combination of Vinorelbine and Herceptin in metastatic breast cancer (BC) patients – A phase II study. Shalmon AY, Merlet I, Gips M, Hubert A, Peretz T. ISCORT-1. Eilat, Israel. February 2002.
“Prognostic factors for patients with metastatic breast cancer treated with paclitaxel.” Nisman B, Barak V, Hubert A, Kadouri L, Lyass O, Peretz T. ISCORT-1. Eilat, Israel. February 2002.
“Neoadjuvant treatment of invasive breast cancer patients who received Taxol and Epirubicin combination: Two centers phase II study.” Sarid DL, Ron I, Hubert A, Wigler N, Inbar MJ, Peretz T. ISCORT-1. Eilat, Israel. February 2002.
“The role of Irinotecan (CPT-11) in the management of advanced gastric cancer.” Hubert A. (Oral Presentation) International Meeting GI Malignancies can be Prevented and Treated. Dead Sea, Israel, January 2002.
Protective effect of Amifostine (AMF) on Doxil/Caelyx induced Plamr-Plantar Erythrodsesthesia (PPE) in Patiens with advanced cancer. Lyass O, Lotem M, Edlemann D, Hubert A, Gabizon A. ASCO 2001
"Weekly Vinorelbine (VNB) in the treatment of metastatic breast cancer (MBC)" Lyass O, Uziely B, Peretz T, Hubert A, Brufman G. ASCO 2000, New Orleans, May 2000.
"Phase I trial of Doxil plus Cisplatin (DDP) in patients with advanced malignancies". Lyass O, Hubert A, Tzemach D, Lafair J, Gabizon A. ECCO 10, Vienna. Sept. 1999.
"Breast cancer (BC) - The Israeli Experience". Kadmon I, Hubert A. The 2nd Biannual meeting of the Asian Breast Cancer Society. China, Sept. 1999.
“Does the 103C→T mutation in the ATM gene convey a malignancy risk in Jewish population of North African origin ? A preliminary study. Gips M. Kaduri L. Hubert A. Lerer I. Pokroy E. Nazrian Y. Abeliovich D. Peretz T. UICC, 1st Anglo-Israel Cancer Conference, Eilat, Dec 1998.
“A pilot study of Doxil (Caelyx) in patients with hormone refractory prostate cancer (HRPC).” A Hubert, M.Lotem, Sela, D.Pode, A.Gabizon. UICC, 1st Anglo-Israel Cancer Conference, Eilat, Dec 1998.
“The role of C-ERB B2 (HER2/NEU) in predicting prognosis in newly diagnosed breast cancer.” Rosenbaum E, Brufman G, Hubert A, Nemirovsky I, Livni N, Peretz T. UICC, 1st Anglo-Israel Cancer Conference, Eilat, Dec 1998.
“Chemoradiation in locally advanced pancreatic carcinoma (LAPC). A.Hubert, E. Nemirovsky, E.Rosnebaum, Z.Tochner, M.Vigodaa, Z.Weschler, H.Freund, A.Durst, T.Peretz. UICC, 1st Anglo-Israel Cancer Conference, Eilat, Dec 1998.
“Environmental risk modifiers in BRCA1/2 carriers.” T.Peretz, M.Gibs, L.Kaduri, M.Sagi, A.Hubert, B.Uziely, I.Lerrer, O.Lyass, N.Weinberg, N.I.Hesching, O.Drize, D.Abeliovich. UICC, 1st Anglo-Israel Cancer Conference, Eilat, Dec 1998.
“Clinical utility of TPS in breast cancer.” Barak V. Nisman B. Roisman I. A.Hubert. Peretz T. ISOBM, Tumor Biology, 19,S2: 59, Umea, Sweden, 1998.
“Frequency of Asheknazi mutations in BRCA1 and BRCA2 genes in prostate cancer patients in Israel.” A.Hubert, T.Peretz, L.Kaduri, M.Sagi, N.Weinberg, I.Lerer, D.Abeliovich. ASCO, Los Angeles, May 1998.
“BRCA1 and BRCA2 sequencing in patients with hereditary features of breast cancer and ovarian cancer who were not found to carry the Ashkenazi mutations.” L.Kaduri, D.Abeliovich, A.Hubert, M.Sagi, M.Gips, N.Weinberg, I.Lerer, T.Peretz. ASCO, Los Angeles, May 1998.
“A pilot study of Doxil (Caelyx) in patients with hormone refractory prostate cancer (HRPC).” A. Hubert, M.Lotem, M.Sela, D. Pode, A.Gabizon. 8th International Congress on Anti-Cancer Treatment. Paris, Feb. 1998.
“Clinical and histological characteristics of breast and ovarian cancer carrying the founder Ashkenazi mutations in BRCA1/BRCA2 genes.” T.Peretz, M.Gips, L.Kaduri, L.Heching, A.Hubert, M.Sagi, D.Abeliovich. IATMO Conference, Jerusalem 1997.
“Evaluation of response and prognosis in breast cancer patients by TPS” V. Barak, I. Nisman, A.Hubert, T. Peretz. ISOBM, Tumor Biology 18:51, Switzerland, 1997.
“Hormonal risk factors in breast (BC) and ovarian (OC) patients carrying the Ashkenazi mutations 185del AG(101), 5382insC(1-2) in BRCA1 and 6174delT(2) in BRCA2.” M.Gips, L.Kaduri, M.Sagi, A.Hubert, O.Paltiel, A.Shushan, I.Heching, I.Lehrer, D.Abliovich, T.Peretz. ASCO, Denver, May 1997.
“Clinical and Histological Characteristics of Breast and Ovarian Cancer Patients carrying the BRCA1/BRCA2 Mutations.” M.Gips, L.Kaduri, D.Abeliovich, I.Lerer, A.Hubert, M.Sagi, T.Pertez. 7th International Congress on Anti-Cancer Treatment, Paris, France, 3/97.
More in PubMed